Bayer (BAYN GY) to invest USD 2.2bln in a new manufacturing site in the US

Large-scale US manufacturing commitments by European pharma groups have become a recurring pattern in the current tariff and trade-policy environment, with such announcements typically framed as securing domestic supply chains and defusing the threat of duties on imported medicines. The market read on episodes of this kind has tended to split: near-term, heavy greenfield capex weighs on free cash flow and raises questions on returns discipline, while the strategic value lies in pre-empting punitive trade measures and in potential regulatory goodwill. For Bayer specifically, any sizeable allocation of capital carries extra weight given the group's history of constrained balance-sheet flexibility and litigation overhang, so the funding mix and phasing matter more than the headline number. The usual follow-ons are the site location and timeline, any attached state or federal incentives, and whether peer European drugmakers match with comparable commitments, which would confirm this as a sector-wide reshoring wave rather than a company-specific decision. Watch for management commentary on whether the spend is incremental or a reallocation from elsewhere in the capex budget.